18476573. COMPOSITIONS, SYSTEMS, AND METHODS FOR TREATING CANCER USING ALTERNATING ELECTRIC FIELDS AND APOPTOTIC CANCER CELL VACCINATION simplified abstract (Novocure GmbH)

From WikiPatents
Revision as of 03:57, 16 April 2024 by Wikipatents (talk | contribs) (Creating a new page)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

COMPOSITIONS, SYSTEMS, AND METHODS FOR TREATING CANCER USING ALTERNATING ELECTRIC FIELDS AND APOPTOTIC CANCER CELL VACCINATION

Organization Name

Novocure GmbH

Inventor(s)

Tali Voloshin-sela of Haifa (IL)

Yiftah Barsheshet of Haifa (IL)

Gadi Cohen of Haifa (IL)

COMPOSITIONS, SYSTEMS, AND METHODS FOR TREATING CANCER USING ALTERNATING ELECTRIC FIELDS AND APOPTOTIC CANCER CELL VACCINATION - A simplified explanation of the abstract

This abstract first appeared for US patent application 18476573 titled 'COMPOSITIONS, SYSTEMS, AND METHODS FOR TREATING CANCER USING ALTERNATING ELECTRIC FIELDS AND APOPTOTIC CANCER CELL VACCINATION

Simplified Explanation

The patent application abstract describes immunogenic compositions and systems for treating cancer by applying an alternating electric field to cancer cells and irradiating them. The methods also involve administering the treated cancer cells back to the subject. The immunogenic compositions consist of populations of isolated, apoptotic cancer cells.

  • Explanation of the patent/innovation:

- Immunogenic compositions and systems for treating cancer - Methods involving application of an alternating electric field to cancer cells and irradiation - Administration of treated cancer cells back to the subject - Compositions comprising populations of isolated, apoptotic cancer cells

Potential Applications

The technology can be applied in cancer treatment, specifically in reducing the viability of cancer cells, treating cancer, reducing tumor volume, and preventing an increase in tumor volume in living subjects.

Problems Solved

This technology addresses the challenges of cancer treatment by providing a method to reduce the viability of cancer cells, treat cancer effectively, and prevent tumor growth in living subjects.

Benefits

The benefits of this technology include improved cancer treatment outcomes, reduced tumor volume, and potential prevention of tumor growth in living subjects.

Potential Commercial Applications

The technology has potential commercial applications in the field of oncology, pharmaceuticals, and biotechnology for developing innovative cancer treatment methods and products.

Possible Prior Art

One possible prior art could be the use of electric fields in cancer treatment, such as electroporation techniques for delivering drugs into cancer cells. Another could be the use of immunogenic compositions in cancer therapy, focusing on stimulating the immune system to target cancer cells.

Unanswered Questions

How does the alternating electric field affect the cancer cells at a molecular level?

The article does not delve into the specific mechanisms by which the alternating electric field impacts cancer cells at a molecular level. Further research may be needed to understand the exact processes involved.

What are the potential side effects or limitations of this treatment method?

The article does not mention any potential side effects or limitations of the treatment method. It would be essential to investigate any adverse effects or constraints associated with the application of alternating electric fields and irradiation in cancer treatment.


Original Abstract Submitted

Immunogenic compositions and systems are disclosed, as well as methods for producing the immunogenic compositions. Compositions, systems, and methods of reducing viability of cancer cells and treating cancer, as well as methods of reducing volume of a tumor and/or preventing an increase in volume of a tumor present in a body of a living subject, are also disclosed. The systems and methods involve application of an alternating electric field to cancer cell(s) (before or after isolation from a targeted portion of a subject), and irradiation of the isolated and treated cancer cell(s). The methods may further include administration of the irradiated, treated cancer cells back to the subject from which the cancer cell(s) were isolated, and/or application of an alternating electric field to the subject. The immunogenic compositions comprise populations of isolated, apoptotic cancer cells.